Better biomarkers could end the long diagnostic delay in mitochondrial myopathy

Mitochondrial myopathies are hard to diagnose. They arise from structural or functional mitochondrial defects that impair oxidative phosphorylation and ATP production. The energy deficit often reaches beyond muscle to the brain, heart, kidneys, and endocrine system, producing a multi-systemic picture that is easy to misread. As a result, diagnosis is often delayed and many cases are never identified.

This is a narrative review in the series Advances in Clinical Chemistry. The authors examine current and emerging biomarkers for mitochondrial myopathy. They emphasize that mitochondria are more than power plants. They serve as hubs for biosynthetic pathways, calcium homeostasis, thermogenesis, apoptosis, and redox-sensitive signaling that influences gene expression. Disruption of these functions, whose molecular consequences are still being worked out, is thought to underlie disease progression and the wide variation between patients.

Based on the abstract, the main output is a proposed diagnostic framework. It aims to improve diagnostic accuracy, limit unnecessary procedures, and ensure timely access to therapies and genetic counseling. The abstract does not name the specific biomarkers reviewed or report performance figures such as sensitivity or specificity.

The implications reach beyond rare disease. Mitochondrial dysfunction is a central theme in aging research, and better tools for measuring it could eventually inform how mitochondrial health is assessed in broader populations. For now, the paper's value is in structuring how clinicians sequence testing.

Caveats: this summary rests on the abstract alone. The review methods, biomarker details, and the framework's validation status are not available, so the claims cannot be independently assessed. Reviews of this type also reflect the authors' selection and interpretation of the literature.